Are the New Guidelines for the Use of Lipid-Lowering Agents Sound, and Should Their Adoption Be Encouraged?

THE “PRO” SIDE

The American College of Cardiology/American Heart Association (ACC/AHA) 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults will, if followed, usher in an era of more effective, more efficient, and more rational pharmacotherapy for cardiovascular risk reduction.

For as long as elevated cholesterol has been recognized as a cardiovascular risk factor and drugs have been available to lower cholesterol, guidelines for their use have existed. The prevailing perspective has been based on the dogma that elevated cholesterol (especially low-density lipoprotein [LDL] cholesterol) causes atherosclerosis, and therefore that lowering it by any means (drugs or diet) reduces the risk of cardiac events. This simple “lipid hypothesis” is congruous with the blood pressure hypothesis of cardiovascular disease and has shaped a generation of clinicians’ approach to risk reduction. Evidence to support the idea that “lower is better” has arisen to lend apparent support, and guidelines (based mainly on consensus) have proffered targets and threshold lipid values. However, the evidence to support this “targeted therapy” approach is purely observational, showing only a correlation between cholesterol values and cardiovascular risk. This correlation does not prove the lipid hypothesis any more than positive associations between C-reactive protein or homocysteine and cardiovascular risk proves their causal role. The trail of fallacies leading from association to perception of causation that has arisen from lipid studies is well described. The lipid hypothesis has also been weakened by the SEAS trial and ENHANCE trials of ezetimibe, and beliefs about the beneficial effects of high-density lipoprotein cholesterol are currently under siege.

One inconvenient fact has always overshadowed the targeted approach: there have been no randomized controlled trials (RCTs) in which drug therapy was titrated to achieve particular lipid targets. Rather, nearly all RCTs have involved giving a fixed dose of study drug to defined patient groups. Such trials lend no support to the lipid hypothesis but do show that drugs, especially statins, can reduce cardiovascular risk. This “tailored therapy” approach has long been advocated on the basis of analyses showing greater net benefit and less overall drug exposure than the targeted approach.

The ACC/AHA 2013 guideline resoundingly advocates the tailored therapy approach to cardiovascular risk reduction. This will be a major change for many clinicians but, compared with the targeted approach, is more likely to result in judicious use of statins in patients most likely to benefit, as well as reducing the cost, toxicity, and complexity of polytherapy and reducing the costs of repeated cholesterol level measurements, physician visits, and dosage adjustments.

The new guideline singles out statins as the most appropriate drug therapy as an adjunct to healthy lifestyle. It goes further by acknowledging RCT evidence that more statin is more effective than less statin, recommending “high-intensity” statin therapy for the highest-risk patients. This recommendation is rational. If it is followed, its effect will be to produce a gradient of fixed statin doses commensurate with individual cardiovascular risk. The guideline focuses on the following 4 patient populations: (1) patients who already have atherosclerotic heart disease (a well-studied population in which fixed-dose statin is effective regardless of cholesterol levels); (2) patients with diabetes mellitus older than 40 years of age (for whom RCTs support use of fixed-dose statin); (3) primary prevention patients with a 10-year risk of atherosclerotic heart disease above 7.5% (another population with RCT evidence to support fixed-dose statin use, albeit with lower absolute chance of benefit than the first 2 groups); and (4) patients with profoundly elevated LDL cholesterol signifying familial hypercholesterolemia (based on observational evidence). These patients are readily identifiable in general practice, with many of them requiring no measurement of blood cholesterol (groups 1 and 2) or only an initial cholesterol measurement for risk stratification (group 3) or to detect familial hypercholesterolemia. In my view, the guideline does not go far enough to discourage repeat cholesterol measurement, despite its forthright predicate that no cholesterol goals are justified.

The new guideline introduces a new risk assessment tool, which is somewhat welcome because it is bolstered (relative to the Framingham tool) by recent observational evidence involving “nonHispanic Caucasian and African American” men and women. Contemporizing a cardiovascular risk tool temporally, geographically, and in relation to ethnicity is usually worthwhile. However, the new tool has been criticized for overestimating risk and driving increased statin use. Further research is required to optimize the new tool and determine...
which of the many available schemes has superior In which populations. Fortunately, acceptance of the new ACC/AHA risk calculator is not required for applying the guidelines.

For practical, evidence-based, patient-centred reasons, clinicians should become familiar with the new ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults and follow it whenever possible.

References
ACC/AHA guideline on the treatment of blood cholesterol. As would be expected, both the US and Canadian guidelines recommend the use of statin-based therapy in higher-risk individuals, i.e., those with established atherosclerosis, most individuals with diabetes mellitus, and those with low-density lipoprotein (LDL) cholesterol above 5 mmol/L. Moreover, the CCS guidelines, like the ACC/AHA and the European recommendations, put statins at the cornerstone of therapy, alongside lifestyle modifications.

Surprisingly, however, the ACC/AHA and CCS guidelines differ in some aspects. First, in addition to recommending the use of statin-based therapy in higher-risk patients, the ACC/AHA guideline recommends statin therapy for most patients considered at low or moderate risk (estimated 10-year risk of atherosclerotic cardiovascular disease ≥ 7.5%). Although it has not been confirmed, we might assume that these guideline changes would most likely result in a greater number of patients being medically treated with statins. On the other hand, the CCS guideline includes the following list of conditions defined as representing high risk of ischemic cardiovascular disease: presence of clinical atherosclerosis or abdominal aortic aneurysm; adjusted Framingham risk score ≥ 20%; diabetes for more than 15 years in patients older than 30 years of age; diabetes in any patient older than 40 years of age; presence of microvascular disease; presence of high-risk kidney disease (estimated glomerular filtration rate [eGFR] ≤ 45 mL/min per 1.73 m² or albumin–creatinine ratio ≥ 30 mg/mmol or eGFR ≤ 60 mL/min per 1.73 m² combined with albumin–creatinine ratio ≥ 3 mg/mmol); or high risk hypertension.

Second, even though both panels recommended that therapy be initiated on the basis of a calculated cardiovascular risk, 2 different approaches are presented. As in previous CCS guidelines, the updated CCS guidelines advocate use of a modified Framingham risk score, whereas the ACC/AHA guideline recommends use of the new pooled cohort equations. Although this new risk engine may provide some benefits (because it is derived from several cohorts and measures the risk of hard cardiovascular end points), some are concerned that it may not have been validated properly and may therefore overestimate risk. On the other hand, the modified Framingham risk score also has its limitations, one of which is poor uptake by primary care clinicians, especially to guide therapies for primary prevention.

Third, the use of LDL cholesterol targets in the management of dyslipidemia was dropped by the ACC/AHA guidelines for the following reasons: (1) clinical trials have not aimed at achieving specific levels of LDL cholesterol but rather have randomized patients to fixed-dose medication regimens and consequently, the optimal treatment targets are not known; (2) several trials of combination therapy have not reported improved event rates relative to statin therapy alone; and (3) it is not known what benefits would be derived from selecting one target over a higher one. Instead, a novel yet controversial approach to treatment according to the patient’s risk phenotype is advocated, with statins of different potency to be prescribed according to the patient’s risk assessment.

In the end, the ACC/AHA guidelines went for a simplified approach, with a tool that is not validated, in the hope of greater uptake of the guideline. As a result, a greater number of Americans are being treated with evidence-based therapy. In contrast, the CCS guidelines have taken a more conservative approach, electing to continue to support the concept of LDL cholesterol targets in view of cardiovascular risk calculated with a validated risk assessment tool that has been in longer use.

As for the question at hand—whether the new guidelines for the use of lipid-lowering agents are sound and whether their adoption should be encouraged—a few considerations must be taken into account before electing to rigorously follow the CCS guidelines or, for that matter, the ACC/AHA guideline: (1) there have been no randomized trials confirming that use of the modified Framingham risk score (or the pooled cohort equations) to guide therapy provides optimal outcomes; and (2) the risk categories used internationally (low risk < 10%, intermediate risk 10%–19%, high risk ≥ 20%) are arbitrary and do not rest on scientific evidence.

In conclusion, a guideline should be viewed simply as a framework to guide clinical decision-making. Regardless of the recommendations in any guideline, individual decisions should always be made with respect to the specific patient, especially in primary prevention, where additional conditions not taken into account in the risk assessment engines may significantly influence risk (e.g., inflammatory conditions, high-risk ethnic background, or extremes of cardiovascular risk factors) and should be considered in the decision-making process. Moreover, we should always give consideration to the potential for cardiovascular risk reduction, adverse drug reactions, and drug–drug interactions, as well as to patient preferences, before initiating medical therapy, rather than systematically adopting a “one treatment fits all” approach.

References


**Chantal Pharand**, BPharm, PharmD, BCPS
Vice-Dean, Undergraduate Studies
Faculty of Pharmacy
Université de Montréal
Montréal, Quebec

Dr Pharand is also a Clinical Pharmacist, Cardiovascular Risk Reduction Clinic, Hôpital du Sacré-Cœur de Montréal, Montréal, Quebec.

**Competing interests:** None declared.